AJMC reports peptide regulation debate intensifying after FDA panel vote
The trade outlet frames a contested advisory committee vote as the trigger for renewed argument over how peptide therapies should be regulated.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 25 15:52 ETSource: ajmc.com
The wire
- 01AJMC reports that a controversial FDA advisory panel vote has sharpened the debate over peptide regulation.
- 02Compounders, prescribers and telehealth operators working with peptide therapies track advisory committee signals closely because they often precede agency policy shifts.
- 03The panel, product and vote tally behind the story are not specified in the item; the FDA's formal response to the committee remains the thing to watch.
From the source
Read at ajmc.comPeptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
